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ABSTRACT  
Purpose Angiogenesis plays a critical role in tumor growth. This phenomena is regulated by 
numerous mediators such as vascular endothelial growth factor (VEGF). CBO-P11, a cyclo-peptide, 
has proven to specifically bind to receptors of VEGF and may be used as targeting ligand for tumor 
angiogenesis. We herein report the design of novel nanoparticles conjugated to CBO-P11 in order to 
specifically target tumor site. 
Methods The conjugation of CBO-P11 on the surface of poly(vinylidene fluoride) (PVDF) 
2 
 
nanoparticles was investigated using the copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition 
known as ―click‖ reaction. First, CBO-P11 was modified with a near-infrared (NIR) cyanine dye 
bearing an alkyne function, allowing both ―click‖ coupling on azido-modified nanoparticles and 
fluorescence labelling. Each step of this nanodevice construction was judiciously performed in 
aqueous solution and successfully characterized. The cytotoxicity of nanoparticles was evaluated in 
human brain endothelial cell (HCMEC) line and their affinity for VEGF receptors was determined 
via fluorescence-based uptake assays on porcine aortic endothelial (PAE) cell line. 
Results Nanoparticles were found to be spherical, dense, monodisperse and stable. Furthermore, 
no cytotoxicity was observed after 4 days of incubation demonstrating the biocompatibility of 
nanoparticles. Fluorescence highlighted the specific interaction of these functionalized 
nanoparticles for VEGF receptors suggesting that the targeting peptide bioactivity was retained.  
Conclusions These results demonstrate the potential of these functionalized nanoparticles for 
targeting tumor angiogenesis and their possible use as multifunctional plateform for cancer treament 
if coupled with therapeutic agents. 
KEY WORDS Nanoparticles, PVDF, tumor targeting, angiogenesis, ―click‖ chemistry, cyclo-
peptide.   
 
INTRODUCTION 
Lack of selectivity in cancer therapies is one of the major limitations of chemotherapies due to 
their strong side effects. The quest for tumor-specific treatments has led to the development of 
nanoparticulate drug delivery systems (1). Indeed, polymeric nanoparticles gained considerable 
attention in recent years because they offer two strategic pathways: passive and active targeting. 
Passive targeting occurs by passive accumulation of polymeric nanoparticles preferentially in tumor 
tissues by enhanced permeation and retention effects of malignant vessels compared to healthy 
vessels (2). In the other hand, nanoparticles which have a high surface area can carry a large number 
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of biological molecules such as ligands that specifically bind to overexpressed receptors in the 
tumor region, this is named active targeting. Among targeting agents, anti-angiogenic peptides have 
received intense interest (3). Angiogenesis is the development of new blood vessels from existing 
ones and plays a critical role in controlling tumor growth and metastasis. Indeed, Folkman 
hypothesized in 1971 that tumor growth requires the elaboration of vascular network to supply 
nutrients and oxygen avoiding hypoxia and tumor cell apoptosis (4). Angiogenesis is regulated by a 
balance of positive and negative mediators. Among them, vascular endothelial growth factor 
(VEGF) is a key factor in tumor growth; it regulates endothelial cell proliferation, permeability, and 
survival. VEGF exerts its action via binding to two main receptor-type tyrosine kinase: VEGFR-1 
(known also as Flt-1) and VEGFR-2 (known also as KDR) (5-7). These receptors are overexpressed 
on tumor-associated endothelial cells (8-10). Thus, blocking tumor angiogenesis appears to be an 
attractive target to inhibit specifically tumor growth without damaging normal cells. In our 
laboratory, we have synthesized a 17-amino acid molecule designated cyclo-peptidic vascular 
endothelial growth inhibitor (cyclo-VEGI or CBO-P11) encompassing residues 79–93 of VEGF 
which are involved in the interaction with VEGFR-2 (11). CBO-P11 shows a micromolar affinity 
for VEGFR-2 and can be used as a tumor targeting agent. 
In this paper, we present an elegant strategy for the conjugation of this peptidic ligand on 
poly(vinylidene fluoride) (PVDF) nanoparticles which could be used as novel tool for targeting 
tumor angiogenesis. PVDF was chosen due to its known non-toxicity, biocompatibility, chemical 
stability properties (12). Commercially available PVDF devices are in use for medical application. 
For example, XIENCE V
TM
 utilizes the MULTI-LINK VISION
®
 stent, the antiproliferative drug 
everolimus, a fluorinated polymer drug carrier, poly(vinylidene fluoride-co-hexafluoropropylene) 
(PVDF-HFP) and a stent-specific delivery system (13). PVDF is also used for surgical mesh 
(DynaMesh® for abdominal hernia repair) (14-16). Others applications have been as well reported 
such as membranes for osteoblast adhesion (17) or nerves regeneration (18). Although PVDF has 
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been used for biomedical applications, literature lacks reports about the use of PVDF nanoparicles 
as nanocarrier. PVDF is a hydorphobic polymer suggesting that it could be coated with a 
hydrophilic layer to get a core/shell structure and then can be used as drug delivery system. 
According to an optimized process from a preliminary study (19), nanoparticles were consequently 
coated with poly(acrylic acid) (PAA) using electron-beam irradiation yielding PVDF-g-PAA 
nanoparticles. 
To achieve the conjugation of CBO-P11 to PVDF-g-PAA nanoparticles without modifying the 
bioactivity of targeting peptide, we investigated ―click‖ reaction which has received much attention 
for preparation of bioconjugated systems due to its high degree of selectivity and stability and its 
potential use under physiological aqueous conditions (20-22). We have chosen to take advantage of 
Huisgen 1,3-dipolar cyclo-addition to conjugate alkyne-peptide and azido polymeric nanoparticles 
(Scheme 1). First, CBO-P11 was coupled with a fluorescent cyanine dye bearing an alkyne function 
(Scheme 2). Subsequently, carboxylic functions on the surface of PVDF-g-PAA nanoparticles were 
coupled with an amine-terminated azido spacer arm derived from oligoethylene glycol. This 
ethylene glycol chain aims to increase the hydrophilicity of nanoparticles and space the future 
biologically active molecule away from the core of the nanoparticles.  
A detailed characterization was performed to assess the morphology of nanoparticles and the 
grafting location. Furthermore, in vitro cytotoxicity and uptake studies were performed on 
endothelial cells in order to check the biocompatibility of these nanoparticles and the keeping of the 
peptide affinity for VEGF receptors.  
MATERIALS AND METHODS 
Materials. The following chemicals were purchased from Sigma-Aldrich [Saint-Quentin 
Fallavier, France] and used as received: paraffin Wax, potassium persulfate, perfluorooctanoic acid 
(POA), acrylic acid (AA) stabilized with 200 ppm hydroquinone, propargylamine, piperidine, 
diisopropylethylamine (DIEA), copper sulfate, sodium ascorbate, trifluoroactic acid (TFA), 
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triisopropylsilane (TIS) and 4-carboxy TEMPO. Vinylidene fluoride (VF2) monomer was provided 
by Solexis [Yverdon-les-Bains, Switzerland]. N-hydroxybenzotriazole (HOBt), Ethyl-
3(3dimethylaminopropyl)carbodiimide (EDC), phenol and potassium bromide were obtained from 
Fluka [Saint-Quentin Fallavier, France]. The HPLC grade solvents dichloromethane (DCM), 
tetrahydrofurane (THF) and acetonitrile (ACN) were provided from VWR [Fontenay sous Bois, 
France]. N-methylpyrrolidone (NMP) was purchased from Applied Biosystems [Villebon-sur-
Yvette, France]. Tertio-butanol (t-BuOH) was purchased from Acros Organics [Geel, Belgium]. 
Fmoc-Lys(Boc)-OH was provided by Novabiochem [Darmstadt, Germany]. Thioanisole and 
ethylenediaminetetraacetic acid (EDTA) were purchased from Alfa Aesar. Endothelial growth 
medium (EGM-2) Bulletkit was purchased from Cambrex [Walkersville, USA]. Human brain 
endothelial cells (HCMEC) were kindly provided by P.O. Couraud [Institut Cochin, Paris, France] 
and were grown as previously reported by Weksler et al. (18). Porcine aortic endothelial cells stably 
transfected with VEGFR-2 (PAE) were a gift from Dr. Lena Claesson-Welsh [Ludwig Institute, 
Uppsala, Sweden]. Dulbecco's modified eagle medium (DMEM) was purchased from Invitrogen 
[Cergy Pontoise, France]. 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene 
disulfonate (WST-1) was provided from Roche Applied Science [Indianapolis, IN, USA]. 
Synthesis of PVDF Nanoparticles. PVDF nanoparticles were prepared by emulsion polymerization 
of corresponding monomer (VF2) as previously described (19). Two different syntheses were run: in the 
presence or in the absence of surfactant. Briefly, 3 litres of an aqueous solution consisting of paraffin 
(40 g, 10% in weight of monomer), potassium persulfate initiator (400 mg, 1.5 mmol) and only for the 
second synthesis, perfluorooctanoic acid surfactant (10 g, 24 mmol) and potassium hydroxide (1.5 g, 27 
mmol) were put in a stirred autoclave under vacuum. The mixture was then heated to 40°C and stirred at 
800 rpm. The reactor was fed with VF2 gaseous monomer (400 g, 6.2 mol) to reach desired pressure 
(100 bars) while the temperature carried on rising up to 80°C. When pressure decreased under 80 bars 
for the first synthesis and 60 bars for the second one, stirring was stopped. The supernatant containing 
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paraffin was removed and the latex dispersion made of PVDF nanoparticles in suspension was got back 
as it. 
In Situ Radiation Grafting of PVDF with Acrylic Acid. PAA grafting onto PVDF nanoparticles 
was directly achieved upon -irradiation of PVDF nanoparticles dispersed (10 mg/ml) in a 2% AA 
aqueous solution. The irradiation was performed at room temperature under vacuum, using a 
Gammacell 3000 Elan, MDS Nordion irradiator from a 
137
Cs source in the 1–10 kGy dose range at 0.33 
kGy/h dose rate. Then, the mixture was washed with distilled water by filtration on 0.05 m Millipore 
membranes to completely remove the homopolymer and the unreacted monomer. 
Covalent Coupling of Spacer Arm. The spacer arm noted mTEG was synthesized as described in a 
previous paper (24). mTEG (10 eq.) was coupled to PVDF-g-PAA nanoparticles (5 mg/ml) via an amide 
bond to the carboxylic acid functions of PAA using EDC (10 eq.), at room temperature for 24 h under 
mechanical stirring. Then, the dispersion was purified by dialysis using Spectra/Por membrane (MW: 
50000 Da) for 3 days. The PVDF-g-PAA-mTEG nanoparticles were kept in water to avoid aggregation. 
Synthesis of Fmoc-Lys(Boc)-propargyl amide [1]. To a solution of Fmoc-Lys(Boc)-OH (3.74 
g, 8 mmol) in DCM (60 ml), EDC (1.7 ml, 9.6 mmol) and HOBt (1.47 g, 9.6 mmol) were added. 
The mixture was stirred at room temperature for 30 min. Then, propargylamine (1.1 ml, 16 mmol) 
was added and the resulting solution was stirred for 12 h. The crude product dissolved in DCM was 
washed with 10 ml of 1 M HCl solution. A white precipitate was formed and removed by filtration. 
The organic phase was washed with water, dried over MgSO4 and solvent was evaporated under 
reduced pressure. The solid was rinsed with diethyl ether and dried to give a pale yellow solid (3.56 
g, 88%) without further purification. The product was analyzed by reversed-phase HPLC with the 
following gradient: 30% of eluant B for 5 min and 30-100% for 10 min ; detector: 214 nm, tr = 21.8 
min and purity = 95%. 
1
H NMR (300 MHz, CDCl3): δ = 1.34-1.55 (m, 4 H, CH2CH2CH2CH2), 1.45 
(s, 9 H, (CH3)3C), 1.69 (q, 1 H, J = 7.6 Hz, CHCH2CH2), 1.86 (q, 1 H, J = 7.6 Hz, CHCH2CH2), 
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2.16 (br s, 1 H, CH2C≡CH), 3.11 (br s, 2 H, CH2CH2NH), 4.03 (br s, 2 H,  NHCH2C≡CH), 4.23 (t, 2 
H, J = 5.9 Hz, CHCH2 and NHCHCO), 4.41 (d, 2 H, J = 5.5 Hz, CHCH2CO), 4.73 (br s, 1 H, 
NHBoc), 5.74 (d, 1 H, J = 6.4 Hz, NHFmoc), 6.83 (br s, 1 H, CONHCH2), 7.31 (t, 2 H, J = 7.3 Hz, 
CHAr), 7.41 (t, 2 H, J = 7.0 Hz, CHAr), 7.59 (t, 2 H, J = 6.7 Hz, CHAr) and 7.77 (t, 2 H, J = 7.1 Hz, 
CHAr). 
13
C NMR (75.5 MHz, CDCl3): δ = 22.5 (CH2CH2CH2), 28.5 ((CH3)3C), 29.2 (CH2CH2CH2), 
29.6 (NHCH2C≡CH), 32.01 (CHCH2CH2), 47.2 (CH2CH2NH),  53.5 (CHCH2), 54.7 (NHCHCO), 
67.2 (CHCH2CO), 71.9 (CH2C≡CH), 75.5 (CH2C≡CH), 79.2 ((CH3)3C), 120.1 (2 CHAr), 125.2 (2 
CHAr), 127.1 (2 CHAr), 127.8 (2 CHAr), 141.4 (2 CAr), 143.8 (2 CAr), 156.5 (COBoc and COFmoc) 
and 171.7 (NHCO). Mass analysis (MALDI-TOF): m/z 528.1900 (calcd for C29H35N3O5Na [M
+
] m/z 
528.5951). 
Synthesis of H2N-Lys(Boc)-propargyl amide [2]. Fmoc-Lys(Boc)-propargyl amide (450 mg, 
0.89 mmol) was dissolved in 3% piperidine in THF (30 ml). After the mixture was stirred for 5 h at 
room temperature, solvent was removed under reduced pressure, and the residue was coevaporated 
three times with toluene. Petroleum ether (10 ml) was added to the crude product and the 
supernatant containing the dibenzofulvene-piperidine adduct was removed. The residue was dried 
under vacuum and was used as it without further purification. Mass analysis (ESI): m/z 284.1968 
(calcd for C14H26N3O3 [M
+
] m/z  284.3666). 
Synthesis of CyTE777-Lys(Boc)-propargyl amide [3]. The CyTE777 NIR dye was synthesized 
as previously reported by Hilderbrand et al. (25). To a solution of CyTE777 (180 mg, 0.22 mmol) in 
a mixture H2O/ACN (1/1) (30 ml), EDC (47 l, 0.26 mmol) and HOBt (40 mg, 0.26 mmol) were 
added. The mixture was stirred at room temperature for 30 min. Then, H2N-Lys(Boc)-propargyl 
amide (156 mg, 550 mol) was added and the resulting solution was stirred for 5 h. The solvent was 
removed under reduced pressure and the residue was used as it without further purification. Mass 
analysis (ESI): m/z 1084.4526 (calcd for C55H75N5O10S3Na [M
+
] m/z 1084.4568). 
Synthesis of CyTE777-Lys(NH2)-propargyl amide [4]. CyTE777-Lys(Boc)-propargyl amide 
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(174 mg, 0.16 mmol) was dissolved in a mixture of DCM/TFA (1/1) (6 ml). After the mixture was 
stirred for 2 h 30 at room temperature, DCM was evaporated under reduced pression. Then, water 
was added and the mixture was freeze-dried. The product was purified by preparative HPLC with 
the following gradient: 0% B for 5 min, increase up to 20% B in 5 min, 20% B for 10 min, increase 
up to 100% B in 10 min and 100% B for 10 min, max  of detector: 740 nm, tr = 33.5 min. ACN was 
evaporated and the aqueous solution was freeze-dried to give a green solid (83 mg, 53%). UV-
visible (H2O): max = 782 nm (49 000 M
-1
cm
-1
). 
1
H NMR (300 MHz, CD3OD): δ = 1.28-1.49 (m, 2 
H), 1.56-1.71 (m, 4 H), 1.77 (s, 12 H), 1.86-2.12 (m, 10 H), 2.53 (t, 1 H, J = 2.6 Hz), 2.55-2.63 (m, 
2 H), 2.65-2.80 (m, 2 H), 2.89 (tt, 8 H, J = 7.2 Hz), 3.08 (t, 2 H, J = 7.0 Hz), 3.91 (t, 2 H,  J = 2.7 
Hz), 4.23 (t, 4 H, J = 7.3 Hz), 4.88-4.93 (m, 1 H), 6.35 (br s, 2 H), 7.19-7.56 (m, 8 H), 8.90 (br s, 2 
H). Mass analysis (ESI): m/z 984.4044 (calcd for C50H67N5O8S3Na [M
+
] m/z 984.4088). 
Synthesis of CyTE777-Lys(CBO-P11)-propargyl amide [5]. CBO-P11, 
cyclo(DFPQIMRIKPHQGQHIGE) peptide with protected side chains was synthesized by Fmoc/t-
butyl batch solid phase synthesis on an Applied Biosystems 433A automated peptide synthesizer as 
previously described by Zilberberg et al. (11). To a solution of side-chain protected CBO-P11 (371 
mg, 0.10 mmol) in NMP (4 ml), EDC (47 l, 0.26 mmol), HOBt (42 mg, 0.26 mmol) and DIEA (66 
l, 0.39 mmol) were added. The mixture was stirred at room temperature for 30 min. Then, 
CyTE777-Lys(NH2)-propargyl amide (78 mg, 80 mol) was added and the resulting solution was 
stirred for 24 h. After addition of water (20 ml), a precipitate was formed, removed by filtration and 
was dried under vacuum. Then, side-chain peptide protections were removed with a solution of 
TFA/phenol/water/thioanisole/TIS (10/0.75/0.5/0.5/0.25 v/w/v/v/v). 10 ml of this solution were 
added to 368 mg of product. The mixture was stirred for 3 h at room temperature. After addition of 
diethyl ether (30 ml), a white precipitate was formed, removed by filtration and was dried under 
vacuum to give a green solid (283 mg, 92%). The product was analyzed by reversed-phase HPLC 
with the following gradient: 30% of eluant B for 5 min, 30-50% for 5 min, 50% for 10 min, 50-
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100% for 5 min and 100% for 5 min; detector: 785 nm, tr = 26.5 min and purity = 90%. UV-visible 
(H2O): max = 787 nm (56 000 M
-1
cm
-1
). Mass analysis (MALDI-TOF): m/z 2943.10 (calcd for 
C140H205N33O29S4 [M
+
] m/z 2942.58). 
Conjugation of CyTE777-Lys(CBO-P11)-propargyl amide to Azido-Nanoparticles by “Click” 
Chemistry. An excess of [5] (2 eq.) was added to a solution of PVDF-g-PAA-mTEG (nanoparticles 
irradiated at 5 kGy) using copper sulfate (0.5 mM) and sodium ascorbate (1 mM) at 40°C for 24 h in a 
mixture of H2O/t-BuOH (1/1) (16 ml). Nanoparticles were washed with a 1 mM EDTA solution in order 
to remove copper catalyst by filtration on 0.05 m Millipore membranes. Then, nanoparticles were 
dialyzed using Spectra/Por membrane (MW: 50 000 Da) for 3 days against water to obtain a 1.4 mg/ml 
PVDF-g-PAA-mTEG-CBO-P11-CyTE777 nanoparticles aqueous suspension. In order to obtain a 
control sample without targeting peptide, PVDF-g-PAA-mTEG-CyTE777 nanoparticles were 
synthesized in a similar way using the fluorescent dye [4]. 
Cytotoxicty Assays. HCMEC were grown on a 0.2% gelatine matrix in EGM-2 at 37°C, 5% CO2 up 
to confluence. After trypsinization, cells were washed with DMEM containing 10% FBS by 
centrifugation (800 rpm for 5 min). One hundred microliters of the cell suspension containing 7.5x10
3
 
cells was inoculated into each well of 96-well plates and cells allowed to settle for one night. 
Nanoparticles (PVDF, PVDF-g-PAA, PVDF-g-PAA-mTEG and PVDF-g-PAA-mTEG-CBO-P11-
CyTE777) were then added at different concentrations (0, 0.1, 0.3, 1.1, 3.3, 11, 33 and 100 g/ml) to 
each well. After 2, 3 or 4 days incubation with nanoparticles (except for PVDF-g-PAA-mTEG-CBO-
P11-CyTE777, incubation for only 3 days), 5 l of WST-1 was added to cell medium and absorbance 
was determined after 2 h at 440 nm using an ELISA microplate reader (Molecular Devices 
Corporation). Results were analyzed using the Softmax Pro 4.0 software (Molecular Devices 
Corporation). The assay was performed in triplicates. Cells were counted using a cell counter (Coulter, 
Becton Dickinson). 
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Cell Uptake Assays. Cell uptake experiments were performed using a porcine aortic endothelial  
(PAE) cell line modified to overexpress VEGFR-2. PAE cells were inoculated into 96-well plates 
and grown up to confluency on a 0.2% gelatine matrix in EGM-2 at 37°C, 5% CO2. They were then 
washed with DMEM and incubated for 45 min at 37°C in the same basal medium . Cells were then 
cultured in incomplete EGM-2 medium in the presence or absence of 100 ng/ml VEGF for 45 min at 
37°C. Nanoparticles (PVDF-g-PAA-mTEG-CyTE777 and PVDF-g-PAA-mTEG-CBO-P11-
CyTE777) were added at different fluorophore concentrations (1.4 µM ; 466 nM ; 155 nM ; 52 nM ; 
17.3 nM ; 5.8 nM ; 1.9 nM ; 640 pM). After a 12-h incubation at 37°C in the presence of 
nanoparticles, PAE cells were washed three times with PBS and 96-well plates were analyzed using 
the Odyssey scanner. 
RESULTS AND DISCUSSION  
Synthesis and Characterization of PVDF Nanoparticles. Radical polymerization in aqueous 
emulsion was used to produce PVDF nanoparticles according to a previously described procedure 
(19). In order to assess the influence of surfactant on the size of these particles, two different 
batches of PVDF nanoparticles were prepared in the presence or in the absence of perfluorooctanoic 
acid (POA). Perfluorinated surfactants present a better active surface due to their high acid strength 
compared to hydrocarbon surfactants and promote micellization at lower concentration  (26). The 
size, morphology and stability of nanoparticles were determined by field emission scanning electron 
microscopy (FESEM), static light scattering (SLS), dynamic light scattering (DLS) and small-angle 
neutron scattering (SANS). Table 1 summarizes data observed by these different techniques. In the 
absence of POA, the particles were two fold larger than in the presence of POA. Surfactant 
stabilized the emulsion and contributed to minimize the size of the nanoparticles. The ratio between 
the radius of gyration and the hydrodynamic radius (Rg/Rh) which is a characteristic of 
nanoparticles morphology was found equal to 0.722 for the synthesis without POA and 0.777 for the 
synthesis with POA indicating that the nanoparticles were in both cases dense spheres (theoretically 
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0.775). Polydispersity index (Ip) of particles was calculated by DLS as a measurement of the 
distribution of size to appreciate the homogeneity of the sample. The very low Ip values indicated 
that PVDF nanoparticles were monodisperse for both syntheses. In addition, the zeta potential 
values found by DLS were around -40 mV and indicated stable dispersions in water. In theory, high 
zeta potential values, being positive or negative, tend to stabilize particle suspension. The 
electrostatic repulsion between particles with the same electric charge prevents the aggregation of 
the spheres (27). The negative values of zeta potential (presence or absence of POA) come from 
initiator sulfonate groups and polymer surface charges. Indeed, PVDF is a dielectric polymer and 
electrons are trapped at its surface. 
In Situ Radio-grafting of Poly(Acrylic Acid) (PAA). Introducing negatively charged 
hydrophilic groups onto hydrophobic PVDF polymer is necessary to confer biological 
hemocompatibility to nanoparticles. These functional groups could also be used for the anchoring of 
biological molecules by covalent binding (28). Acrylic acid (AA) was chosen as the monomer to 
obtain grafted PVDF-g-PAA polymer as its radical polymerization is easy to control. Pending 
carboxylic acid functions could allow subsequent coupling. The lack of reactive functions in PVDF 
makes the functionalization difficult with usual chemical reactions. Thus, irradiation was used to 
create free radicals on the surface of the solid and initiate the polymerization of monomer leading to 
the formation of a grafted polymer. Radiation initiation is one of the cleanest grafting methods 
available since molecular initiator or catalysts are not required. In a previous work, we reported the 
grafting of AA on PVDF nanoparticles after their irradiation (post-radio-grafting) (19). However, 
electron paramagnetic resonance and differential scanning calorimetry studies showed a relative 
instability of radicals initiated under irradiation in comparison with PVDF films, decreasing the 
radical amount available for post-polymerization of AA. In oder to circumvent this problem, PVDF-
g-PAA nanoparticles were directly prepared by irradiation of PVDF nanoparticle suspensions in situ 
in a monomer solution. Additionally, this in situ method allowed us to keep nanoparticles in 
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suspension preventing them from aggregation. Moreover, AA monomers act as radiation protectors 
and reduce the risk of degradation of the polymer substrate by the radiation itself (29). 
In agreement with previous studies (19, 30, 31), the FTIR spectrum of PVDF-g-PAA (Figure 1) 
shows a characteristic absorption band at 1726 cm
-1
 attributed to the C=O stretching vibration of the 
carboxylic acid of PAA. The PVDF CH2 stretching vibrations give absorption bands at 3022 and 
2979 cm
-1
 which are superimposed with the OH vibrations of PAA band in the 2500-3500 cm
-1
 
region. To estimate the grafting yields by FTIR, a calibration curve was performed by integration of 
the C=O stretching band from known amounts of a PAA standard in the KBr pellets (see Figure S1 
in Electronic Supplementary Material). The yields of PAA grafting increase gradually with 
irradiation dose in agreement with the evolution of radical concentration (data not shown). Overall 
grafting yields are low (< 7% w/w) and we assume that grafting occurred mainly onto the 
nanoparticles surface and not in the nanoparticles bulk. Indeed, radiation grafting to polymeric 
nanoparticles proceeds from the substrate surface and as the nanoparticles swell, it progressively 
enters into substrate bulk. This mechanism known as the grafting front mechanism was firstly 
described in Chapiro’s pioneer work in the early 60s  (32). To check this hypothesis, PVDF-g-PAA 
nanoparticles were analyzed by a surface technique named X-ray photoelectron spectroscopy (XPS), 
(see Figure S2 in Electronic Supplementary Material). First, survey spectra confirmed the PAA 
grafting with the presence of O1S ray at 533 eV. Furthermore, ratios of deconvoluted C1S peaks 
allowed a grafting yield estimation of 11 mol% over the 8 nm probed thickness. As the grafting 
yield of the whole nanoparticles was found equal to 2 mol% by FTIR, it consequently suggests an 
enrichment of PAA at the surface of nanoparticles. 
The influence of PAA grafting on the nanoparticles dispersion was investigated by SANS. 
Scattering intensity per unit volume and total concentration unit of both PVDF and PVDF-g-PAA 
nanoparticles at different irradiation doses are shown in Figure 2 (data treatment are shown in 
Electronic Supplementary Material). At high q, the shape of the spectra was similar, indicating that 
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radiografting did not induce any significant change of the size and shape of nanoparticles. They 
remained spherical after irradiation in spite of the presence of PAA. Indeed, the grafting yields 
being low, they have a negligible effect on the nanoparticles morphology. On the opposite at low q, 
the scattered intensity decreased with the irradiation dose. An increase in repulsive interactions due 
to the charges of the increasing number of dissociated carboxylic functions is clearly indicated. 
These repulsive interactions were coroborated by higher negative zeta potential relative to PVDF 
nanoparticles (Table 1) which favours colloidal stability, a very important property for a long blood 
circulation time. 
Coupling of Spacer Arm (mTEG). To increase the hydrophilicity of the polymer, to allow the 
coupling of the targeting peptide and improve its accessibility in the future biological environment, 
a spacer arm was coupled to carboxylic acid functions of PVDF-g-PAA nanoparticles. As a model, 
a short ethylene glycol was firstly chosen as spacer. A modified tetraethylene glycol (noted mTEG) 
with an amine function at one end and an azide function at the other end was prepared (24). The 
amine function was coupled to the carboxylic acid functions of PAA  via an amide bond, using a 
water-soluble carbodiimide (EDC) as coupling agent (scheme 1). FTIR spectrum of PVDF-g-PAA-
mTEG nanoparticles (Figure 1) shows specific amide bond absorptions (1643 and 1572 cm
-1
), NH 
amide (3700-3130 cm
-1
), CH2 ether (2950-2840 cm
-1
), azide stretching vibrations (2112 cm
-1
) and 
decrease of the COOH absorption band, in agreement with the covalent coupling of the amino 
spacer arm. Furthermore, when PVDF-g-PAA-mTEG nanoparticles were analyzed by XPS (see 
Figure S3 in Electronic Supplementary Material), a new peak corresponding to N1S of azide and/or 
amide functions was observed and the deconvoluted C1S ray signal showed the contribution of both 
ether and amide functions. These results confirm that the spacer arm was grafted to nanoparticles 
and not simply adsorbed. The coupling of spacer arm did not modify the size of nanoparticles as 
showed by FESEM and DLS data in Table 1. Furthermore, zeta potential was maintained negative 
and confers a high stability to the nanoparticle suspensions. 
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Synthesis of Fluorescent Alkyne-Modified Peptide and “Click” Coupling on Azido 
Nanoparticles. CBO-P11, a 17-amino acid cyclo-peptide encompassing residues 79–93 of VEGF, 
was synthesized as previously described (Figure 3) (11). CBO-P11 showed to bind to VEGFR-2 and 
inhibits VEGF binding with a half-maximal inhibitory concentration (IC50) of 1.3 M. This high 
affinity makes CBO-P11 a suitable candidate for targeted anti-angiogenic therapy. 
The anchoring of CBO-P11 on polymeric nanoparticles required a method allowing to keep the 
integrity of essential basic amino-acids. The copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition, 
named ―click‖ chemistry has proven to be an easy path to covalently couple azides and acetylenes 
(33-35). To apply this reaction on the azido nanoparticles, CBO-P11 has been modified with a 
pendant alkyne moiety. This acetylene was introduced between a fluorescent cyanine dye 
(CyTE777) (25) and CBO-P11 using lysine as intermediate. The peptide was labelled with a 
cyanine to detect and locate nanoparticles. Cyanines belong to the family of near infrared (NIR) 
probes with emissions above 700 nm. The use of NIR dyes shows relevant advantages, such as 
minimal interfering absorption, inexpensive laser diode excitation, reduced scattering and enhanced 
tissue penetration depth (36). Thus, Fmoc-Lys(Boc)-OH was modified with an alkyne function from 
propargylamine via EDC-mediated amide coupling. Then, after a consecutive protecting group 
removal and amide coupling, we obtained CyTE777-Lys(CBO-P11)-propargyl amide (Scheme 2). 
Then, the fluorescent alkyne-modified peptide [5] was conjugated to azido-functionalized PVDF-
g-PAA-mTEG nanoparticles in a H2O/t-BuOH solvent system (scheme 1). The opportunity to 
perform ―click‖ reaction in aqueous media allowed us to keep nanoparticles in their mother solution 
and limit the risk of aggregation. Additionally, it avoids the use of toxic solvents which is crucial 
for biological applications. After reaction and purification, the fluorescent peptide content was 
estimated by UV spectroscopy and found equal to 4.3 mol%. FTIR spectra show a decrease of azide 
band at 2112 cm
-1
 and an increase of amide bands after reaction (Figure 1), in agreement with a 
covalent coupling. Fluorescence spectra (Figure 4/A) show an absorption maximum exc = 785 nm 
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and an emission maximum em = 843 nm for PVDF-g-PAA-mTEG-CBO-P11-CyTE777 
nanoparticles.  
To demonstrate the potential use of these devices for imaging, fluorescence images of PVDF and 
PVDF-g-PAA-mTEG-CBO-P11-CyTE777 nanoparticles in water suspension were recorded using a 
fluorescence scanner (Odyssey) commonly available in biological laboratories (Figure 4/B). The 
image for labelled nanoparticles (PVDF-g-PAA-mTEG-CBO-P11-CyTE777) shows very bright 
green color whereas the image remains dark when nanoparticles are not labelled with fluorescent 
probe. Nanoparticles did not quench the fluorescence of cyanine after conjugation. The high 
fluorescence intensity suggests a great potential for an application in medical imaging.  
Cytotoxicity Assays. To assess the biocompatibility of functionalized nanoparticles, human 
brain endothelial cells (HCMEC) were exposed to nanoparticles at different concentrations for 2, 3 
or 4 days. Cell viability was then checked by measuring the absorbance of WST-1 reagent on an 
ELISA plate reader (Figure 5). WST-1, a modified tetrazolium salt, is reduced to water-soluble 
formazan in the mitochondria of living cells. This reduction only takes place when mitochondrial 
reductase enzymes are active, and therefore conversion can be directly related to cell viability (37). 
Data revealed the absence of toxicity of the nanoparticles, whatever the concentration used after 
four days of incubation. Unexpectedly, we observed an increase in WST-1 signal under high 
concentrations of nanoparticles, suggesting a slight metabolic effect of these compounds on cells. 
Similar results were obtained using other endothelial cell types from different tissue and animal 
origins, including porcine aortic endothelial (PAE) cells, and human umbilical vein endothelial cells 
(HUVEC) (not shown). From these results, functionalized PVDF nanoparticles thus appeared to be 
biocompatible. 
Cell Uptake Assays. In order to check that CBO-P11 kept its binding affinity for VEGF 
receptors after conjugation on nanoparticles, cell uptake assays were performed on PAE cells which 
were modified to overexpress VEGFR-2. PAE cells were incubated with fluorescent nanoparticles 
16 
 
containing CBO-P11 (PVDF-g-PAA-mTEG-CBO-P11-CyTE777) or with control fluorescent 
nanoparticles without peptide (PVDF-g-PAA-mTEG-CyTE777). Control cells were also incubated 
in the presence of an excess (100 ng/ml) of VEGF to block receptors, thus preventing VEGFR-2-
mediated uptake of nanoparticles. Fluorescence was quantified at different fluorophore 
concentrations (Figure 6). Figure 6/A showed a similar uptake profile with or without VEGF for 
PVDF-g-PAA-mTEG-CyTE777 nanoparticles. In contrast, fluorescence intensity for PVDF-g-PAA-
mTEG-CBO-P11-CyTE777 nanoparticles was significantly higher (22%) in the absence of VEGF 
relative to cells incubated with VEGF (Figure 6/B). This indicates that VEGF receptors on the cells 
were partially responsible for the nanoparticles uptake, suggesting a specific interac tion between 
CBO-P11 and VEGF receptors. Therefore, the anchoring of the VEGF receptor-targeting peptide on 
the surface of nanoparticles did not impede its binding to VEGF receptors. This indicates that 
nanoparticles containing CBO-P11 may represent useful vectors for targeting tumor angiogenesis. 
CONCLUSION 
In this paper, we have developed novel polymeric nanoparticles as tool for targeting tumor 
angiogenesis. CBO-P11, a VEGFR-2-specific cylco-peptide, was successfully conjugated on the 
surface of PVDF nanoparticles using ―click‖ chemistry. The nanoparticles were prepared from 
monomer of PVDF by radical aqueous emulsion polymerization. They were functionalized by in 
situ radiation grafting of acrylic acid in aqueous solution. This process was chosen to prevent 
aggregation and optimize the radical polymerization initiation step. Then, a spacer with azide 
function was coupled to nanoparticles to increase the hydrophilicity of the polymer. In the future, a 
longer poly(ethylene glycol) spacer will have to be considered to provide a better colloidal stability 
and to avoid immune system identification (mode ―stealth‖). CBO-P11 was labelled with a NIR 
cyanine dye bearing an alkyne function which allowed ―click‖ reaction with azide functions on the 
periphery of nanoparticles. From SANS, FESEM, SLS and DLS, nanoparticles appeared spherical, 
dense and monodisperse. SANS data indicated a relative stable dispersion due to electrostatic 
17 
 
interactions of PAA grafted onto PVDF nanoparticles. This stability of the nanoparticles should 
favour a long blood circulation time. IRTF and XPS studies confirmed a grafting on the surface of 
nanoparticles making the reactive functions more available. Furthermore, every synthesis step were 
run in aqueous solution, leaving nanoparticles in a favourable environment for medical application. 
Cytotoxicity assays revealed the absence of toxicity after incubation of nanoparticles on HCMEC 
suggesting the biocompatibility of theses nanodevices. Cell uptake assays showed that 
nanoparticles-conjugated CBO-P11 retained its binding specificity for VEGFR-2. These results are 
very encouraging to use these novel nanodevices for targeting tumor vasculature. In addition, the 
labelling with a cyanine dye may be useful for in vivo optical imaging due to the high depth of NIR 
probes. ―Click‖ chemistry is highly selective and can be broadly applicable to a panel of molecules 
(therapeutic drugs,  imaging agents etc.). As a matter of fact, a combination of these labelled 
nanoparticles with therapeutic agents to obtain multifunctional system for drug delivery is under 
study. 
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ABBREVIATIONS 
AA Acrylic acid 
ACN Acetonitrile 
DCM Dichloromethane 
DIEA Diisopropylethylamine 
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DLS Dynamic light scattering 
DMEM Dulbecco's modified eagle medium 
EDC Ethyl-3(3dimethylaminopropyl)carbodiimide 
EDTA Ethylenediaminetetraacetic acid 
EGM-2 Endothelial growth medium 
ESI Electrospray ionization 
FBS Fetal bovine serum 
FESEM Field emission scanning electron microscope 
FTIR Fourier transform infrared 
HCMEC Human brain endothelial cells 
HOBt N-hydroxybenzotriazole 
HPLC High-performance liquid chromatography 
HUVEC Human umbilical vein endothelial cells 
IC50 Half-maximal inhibitory concentration 
Ip Polydispersity index 
MALDI-TOF Matrix-assisted laser desorption/ionization-time of flight 
mTEG Modified tetraethyleneglycol 
NIR Near-infrared 
NMP N-methylpyrrolidone 
NMR Nuclear magnetic resonance 
PAA Poly(acrylic acid) 
PAE Porcine aortic endothelial cells 
PBS Phosphate buffered saline 
POA Perfluorooctanoic acid 
PVDF Poly(vinylidene fluoride) 
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Rg Radius of gyration 
Rh Hydrodynamic radius  
SANS Small-angle neutron scattering 
SLS Static light scattering 
t-BuOH Tertio-butanol 
TFA Trifluoroactic acid 
THF Tetrahydrofurane 
TIS Triisopropylsilane 
UV Ultra-violet 
VEGF Vascular endothelial growth factor 
VEGFR Receptor of VEGF 
VF2 Vinylidene fluoride 
WST-1 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene 
disulfonate 
XPS X-ray photoelectron spectroscopy 
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TABLE 
 
Table 1. Gyration and hydrodynamic radii (Rg and Rh), polydispersity index (Ip) and zeta potential 
() of PVDF Nanoparticles synthesized with or without surfactant (POA), PVDF-g-PAA, PVDF-g-
PAA-mTEG and PVDF-g-PAA-mTEG-CBO-P11-CyTE777 nanoparticles determined by FESEM, 
SLS, SANS and/or DLS. 
 FESEM SLS SANS  DLS  
 
R(nm) Rg (nm) R(nm) Rh (nm) Ip
c (mV) 
PVDFa 110 ± 5 86 ± 4 ND 102 ± 5 0.070 ± 0.008 -43.9 ± 0.3 
PVDFb 55 ± 5 49 ± 3 61 ± 1 59 ± 4 0.002 ± 0.003 -42.7 ± 0.2 
PVDF-g-PAA 58 ± 5 ND 63 ± 5 103 ± 5 0.228 ± 0.041 -57.3 ± 0.2 
PVDF-g-PAA-
mTEG 
58 ± 5 ND ND 103 ± 5 0.130 ± 0.024 -49.9 ± 0.7 
PVDF-g-PAA-
mTEG-CBO-P11-
CyTE777 
60 ± 5 ND ND 135 ± 9 0.134 ± 0.031 -12.3 ± 4.6 
a Synthesis without POA; b Synthesis with POA; c Ip given by Zetasizer (as Ip tends to 0, monodispersity is high); ND: No determined 
 
LEGEND TO SCHEMES AND FIGURES 
Scheme 1. Functionalization of PVDF nanoparticles. Radio-grafting of PAA, coupling with azido 
spacer arm (mTEG) and ―click‖ conjugation of fluorescent targeting ligand (CBO-P11-CyTE777). 
 
Scheme 2. Synthesis of fluorescent targeting ligand CyTE777-Lys(CBO-P11)-propargyl amide. 
 
Figure 1. FTIR transmission spectra of PVDF, PVDF-g-PAA, PVDF-g-PAA-mTEG and PVDF-g-
PAA-mTEG-CBO-P11-CyTE777 nanoparticles. PVDF nanoparticles were irradiated at 5 kGy. 
 
Figure 2. SANS spectra of PVDF nanoparticles before irradiation and PVDF-g-PAA nanoparticles at 
different irradiation doses. The spectra were normalized to the concentration of nanoparticles in D2O. 
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Figure 3. Chemical structure of CBO-P11. The three basic amino acids essential for the interaction 
with VEGF receptors are in red. Amino acid which allowed the peptide functionalization is in blue. 
 
Figure 4. A/ Normalized excitation and emission spectra of 2.0 M aqueous solutions of PVDF-g-
PAA-mTEG-CBO-P11-CyTE777 nanoparticles. B/ Visible images of PVDF nanoparticles (left top) 
and PVDF-g-PAA-mTEG-CBO-P11-CyTE777 nanoparticles (right bottom). Fluorescence images of 
PVDF nanoparticles (left top) and PVDF-g-PAA-mTEG-CBO-P11-CyT777 nanoparticles (right 
bottom) recorded in water (1.7 g/ml, i.e. 60 M of CyTE777) by Odyssey at 800 nm. 
 
Figure 5. Cytotoxicity profiles for HCMEC. A/ Effect of the nanoparticles on cell viability after a 
3-day incubation with either PVDF, PVDF-g-PAA, PVDF-g-PAA-mTEG or PVDF-g-PAA-mTEG-
CBO-P11-CyTE777. B/ Cell viability in time after incubation with 11 g/ml of nanoparticles. 
 
Figure 6. Fluorescence intensity in PAE cells incubated with A/ PVDF-g-PAA-mTEG-CyTE777 
nanoparticles and B/ PVDF-g-PAA-mTEG-CBO-P11-CyTE777 nanoparticles, with or without 100 
ng/ml VEGF. 
 
Scheme 1. 
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Scheme 2.  
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